Celltrion Keeps Pace With Ustekinumab Rivals
Moves CT-P43 Stelara Biosimilar Into Phase III Trials
Celltrion is looking to keep its ustekinumab biosimilar program in step with those of rival developers, after announcing the start of Phase III trials for its CT-P43 candidate.
You may also be interested in...
Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.